AWRE vs NVDA

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 3/9, indicating significant operational and profitability concerns. Despite strong gross margins and robust year-over-year revenue growth of 33.3%, the company continues to report negative profit and operating margins, resulting in negative ROE and ROA. The absence of an Altman Z-Score prevents a full distress risk assessment, but the current negative earnings and lack of valuation metrics suggest elevated risk. While insider sentiment is moderately positive at 60/100, technical trend signals are bearish, and recent price performance shows deterioration over the medium term.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.